All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The enzyme encoded by this gene catalyzes the first 2 steps, and at least 1 subsequent step, in the conversion of tyrosine to melanin. The enzyme has both tyrosine hydroxylase and dopa oxidase catalytic activities, and requires copper for function. Mutations in this gene result in oculocutaneous albinism, and nonpathologic polymorphisms result in skin pigmentation variation. The human genome contains a pseudogene similar to the 3' half of this gene.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-L117 | Human anti-TYR (YMDGTMSQV) T Cell Receptor, pLXSN | Human | Human | YMDGTMSQV | HLA-A*0201 | retroviral vector | ||
TCR-L118 | Murinized (from Human) anti-TYR (YMDGTMSQV) T Cell Receptor, pMSGV1 | Human | Murinized (from Human) | YMDGTMSQV | HLA-A2 | retroviral vector | ||
TCR-L119 | Murinized (from Human) anti-TYR (YMDGTMSQV) T Cell Receptor[Cysteine-modified], pMSGV1 | Human | Murinized (from Human) | YMDGTMSQV | HLA-A2 | retroviral vector | ||
TCR-L120 | Human anti-TYR (YMDGTMSQV) T Cell Receptor, pMP71 | Human | Human | YMDGTMSQV | HLA-A2 | retroviral vector | ||
TCR-L116Z | Human anti-tyrosinase (aa369-377) T cell receptor, pCDTCR1 | Human | Human | YMNGTMSQV | HLA-A*0201 | Lentiviral | ||
TCR-L117Z | Murinized anti-tyrosinase (aa369-377) T cell receptor, pCDTCR1 | Human | Murinized (from Human) | YMNGTMSQV | HLA-A2 | Lentiviral | ||
TCR-L118Z | Murinized anti-tyrosinase (aa369-377) T cell receptor (Cysteine-modified), pCDTCR1 | Human | Murinized (from Human) | YMNGTMSQV | HLA-A2 | Lentiviral | ||
TCR-L119Z | Human anti-tyrosinase (aa369-377) T cell receptor (Codon optimized), pCDTCR1 | Human | Human | YMNGTMSQV | HLA-A2 | Lentiviral | ||
TCR-L213 | Human anti-Tyrosinase T cell receptor (T58), pCDTCR1 | Human | T58 | Human | YMDGTMSQV | HLA-A*0201 | Lentiviral | |
TCR-L256 | Human anti-Tyrosinase T cell receptor (T43), pCDTCR1 | Human | T43 | Human | YMDGTMSQV | HLA-A*0201 | Lentiviral | |
TCR-L257 | Human anti-Tyrosinase T cell receptor (di111), pCDTCR1 | Human | di111 | Human | YMDGTMSQV | HLA-A*0201 | Lentiviral | |
TCR-L258 | Human anti-Tyrosinase T cell receptor (B12), pCDTCR1 | Human | B12 | Human | YMDGTMSQV | HLA-A*0201 | Lentiviral | |
TCR-YC1222 | Human anti-Tyrosinase T cell receptor (TA4), pCDTCR1 | Human | TA4 | Human | YMDGTMSQV | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1223 | Human anti-Tyrosinase T cell receptor (TD6), pCDTCR1 | Human | TD6 | Human | YMDGTMSQV | HLA-A*02:01 | Lentiviral vector | |
TCR-YC1224 | Human anti-Tyrosinase T cell receptor (UG6), pCDTCR1 | Human | UG6 | Human | YMDGTMSQV | HLA-A*02:01 | Lentiviral vector | |
XS-0623-LX27 | Anti-tyrosinase (PD1/28-20-21 TCR) T cell receptor, pCDTCR1 Vector | Human | 20-21 | Mouse | HLA-A2 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION